Applied Medical Resources v. Covidien
This article was originally published in The Gray Sheet
Executive SummaryCentral California federal court jury rules in favor of Covidien's U.S. Surgical subsidiary, finding that it does not infringe an Applied Medical Resources patent related to trocar seal technology, Covidien says Feb. 20. Filed in 2003, AMR's complaint centered on U.S. Surgical's Versaseal Plus system, which maintains a seal during surgery when instruments are inserted or withdrawn. Morgan Stanley analyst Glenn Reicin estimates that Covidien could have faced damages and associated legal costs totaling about $400 million
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.